Near Patient Diagnostics for Women’s Health
Delivering peace of mind through accurate testing
We Enable the Accurate and Early Diagnosis of Common Conditions that Affect Millions of Women
Our platform provides healthcare providers with the tools needed to diagnose Preeclampsia, Endometriosis, Ovarian Cancer, and Polycystic Ovary Syndrome (PCOS) quickly and accurately by shrinking the lab and bringing it closer to patients.
Preeclampsia*
600,000
Mother and infants lives lost worldwide every year
$6.4 Billion
US annual costs
Endometriosis*
6.5 Million
Women impacted in the US
$78+ Billion
US Economic Burden
Ovarian Cancer
40%
Survival rate in 5 years if detected in stage 3
$10 Billion
Savings by early state detection
Polycystic Ovary Syndrome (PCOS)*
5-20%
women of reproductive age are affected
$8 Billion
US costs to diagnose and treat (2020)
* No test available today.
Our Platform = Our Assay + Our Instrument + Proximity
We’ve taken a bulky, costly, slow, and narrowly focused process and streamlined it down into an integrated, multi-analyte, algorithmic platform that is positioned closer to the patient, enabling faster, more accurate and less costly testing.
Speed
Our platform allows you to processes samples in less than 30 minutes, compared to 2+ hours for ELISA.
Accuracy
Our platform (assay and instrument) has been designed for accuracy, with results of ~98% sensitivity*, ~98% specificity*.
Lower Cost
Multiplex up to 32 analytes in a single run, resulting in efficiencies and reduced operating costs as low as $5 a sample.
Easy on Patients
Our testing protocol requires only 100 µL samples, reducing the impact on the patients.
Broad Use
Our platform can test for Bacteria, Viruses, and Proteins.
Proximity
Our solution is positioned near patients; results are delivered to healthcare providers more rapidly than conventional methods.
* Coronavirus Antigen
Demo of MultiomeDX Readers
Demo of MultiomeDx Assay
The Power of the MultiomeDx Platform
Using 100 µL of blood serum, plasma, or saliva, our platform has been built to minimize impact to patients and for accuracy, speed, and efficiency.
Our Platform Empowers Patients
- It saves patients time
- It saves the patient’s money
- Offers less invasive testing
- Allows the patient to screen for risk factors*
* Requires our mobile app.
| Assay Format | Modified sandwich immunoassay on filter membrane of VF Cartridge |
| Sensor Technology | UV LED excitation to scan 34 well VF cartridge array |
| LOD Sensitivity Specificity | 20 TCID50 98%* 98%* |
| Sample Volume | 100 µL |
| Dynamic Range Sensitivity (for protein detection) | 4 logs 20 pg/mL |
| Detector | Fluorescence measurement on VF Cartridge using proprietary read head and reading algorithm |
| Turnaround Time | <1 hour |
* Coronavirus Antigen
Our Pipeline
Women’s Health Diagnotics
About Us
Our team brings a wealth of experience and expertise to bear on the problem.
Co-Founder Su Dwarakanath has worked in the industry for over 30 years. While at various diagnostics companies, she realized that there is a definite need for Point-of-Care testing that can combine the accuracy of a large diagnostic platform and the speed of POC.
Realizing that the holes in the market could be solved with technology, she combined her assay development skills with her co-founder’s, Sri Satyanarayana, engineering skills to create the MutliomeDx’s AutoVega platform for the development of immune assay with high accuracy and speed.
Su Dwarakanath, PhD
Founder & CEO
Roche,Thermo Fisher Scientific, Bayer Diagnostics, Nano Science Diagnostics
New York University
Sri Satyanarayana, PhD
Founder & CTO
IBM, AT&T Bell Labs, Hughes Research Labs, Philips, Free Electron Technology, Nano Science Diagnostics, Full power Technologies
Columbia University
Kevin Seltzer
CFO
Finance professional with over 20 years of corporate finance, structuring, and management.
New York Law School
Steven Verbinski, MD
CMO
Internist in Hayward, CA. Affiliated with multiple hospitals in the area, including Eden Medical Center and St. Rose Hospital. Conducting various clinical trials.
Duke and Stanford University
Board
Dr. Dev Shukla, Executive Chairman
Rajan Pillai Esq., Advisor
Dr. Sulatha Dwarakanath, CEO & Co-founder
Dr. Srinagesh Satyanarayana, CTO, Co-founder (Observer)
Scientific Advisory Board
Alex Melamed, MD, Gynecologic Oncologist Massachusetts General Hospital/Harvard Medical School
George Caughey MD, Immunologist Critical care UCSF
Alley Tevrizian, MD, Immunologist
Nancy Mozelsio, MD, Immunologist
Mitch Levinson, Serial Entrepreneur
Shailja Dixit, MD, MBA, CEO/founder Curio
Contact Us
Please let us know how we can help and a member of our team will get back to you as soon as possible.